Issue 6, 2015

Identification of a novel class of autotaxin inhibitors through cross-screening

Abstract

Three novel series were generated in order to mimic the pharmacophoric features displayed by lead compound AM095, a lysophosphatidic acid (LPA1) receptor antagonist. Biological evaluation of this array of putative LPA1antagonists led us to the discovery of three novel series of inhibitors of the ectoenzyme autotaxin (ATX), responsible for LPA production in blood, with potencies in the range of 1–4 μM together with good (>100 μg mL−1) solubility.

Graphical abstract: Identification of a novel class of autotaxin inhibitors through cross-screening

Associated articles

Supplementary files

Article information

Article type
Concise Article
Submitted
23 Feb 2015
Accepted
07 May 2015
First published
08 May 2015

Med. Chem. Commun., 2015,6, 1149-1155

Author version available

Identification of a novel class of autotaxin inhibitors through cross-screening

D. Castagna, E. L. Duffy, D. Semaan, L. C. Young, J. M. Pritchard, S. J. F. Macdonald, D. C. Budd, C. Jamieson and A. J. B. Watson, Med. Chem. Commun., 2015, 6, 1149 DOI: 10.1039/C5MD00081E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements